Pilgrim, Micrus to implement SmartSolve

Pilgrim Software (Tampa, Florida), a provider of enterprise compliance and quality management (ECQM) software solutions, said that Micrus Endovascular (San Jose, California), a maker of both implantable and disposable medical devices used in the treatment of cerebral vascular diseases, will implement Pilgrim's SmartSolve solutions through Pilgrim's On-Demand "SaaS" model.

In an effort to increase operational efficiencies and streamline compliance, Micrus said it recognized the need to replace its existing manual training management systems, with a single, robust, enterprise-wide system that could help automate all of its training processes associated with GMP and FDA requirements. Likewise, Micrus chose to replace its previously implemented customized document management system in an effort to increase efficiencies, and to take advantage of Pilgrim's document management solution because it integrates directly with the training system. This further reduces the cost of integration between two disparate systems that would have to be created otherwise.

"We chose to go with Pilgrim due to its robust off-the-shelf solutions and their reputation of superior customer service over the competition," said Fritz Ender, Micrus' director of quality assurance. "Pilgrim's training system suited our requirements very closely. Additionally, by implementing SmartDoc with SmartTrain in tandem, we eliminate the need for integration into a separate document management system."

AMCG to continue as genetics collaborative

Overcoming the challenges of bringing quality and cutting edge genetic and newborn screening (NBS) services to local communities and to children and families with hereditary diseases is extremely complex. It requires coordinated, multifaceted and multidisciplinary efforts that are national, regional, and local and include public, private and not-for-profit partnerships. In order to meet these challenges, the Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB) awarded the American College of Medical Genetics (ACMG; Bethesda, Maryland) a cooperative agreement in 2004 and later renewed it until 2012 to serve as the National Coordinating Center (NCC) for seven similarly-funded Regional Genetics Collaboratives known as the HRSA Genetics Collaboratives.

These seven HRSA/MCHB-funded HRSA Genetics Collaboratives and their NCC are working to improve access to local genetic and newborn screening services, information, and resources for individuals and families with heritable disorders. A major component of the NCC/Genetics Collaboratives system involves using a variety of approaches to link primary care providers, geneticists and other specialist providers, and public health services into a comprehensive medical home that meets all the needs of individuals and families with heritable conditions. Activities at all levels engage consumers and families, with new opportunities for partnerships continually emerging.

Motion launches new clinical workstations

Motion Computing (Austin, Texas) reported a new line of Motion Clinical Workstations (MCW). Highly flexible and fully integrated, the MCWs are designed specifically to support a broad range of clinical workflows.

Motion, the developer of the C5, the industry's first mobile clinical assistant (MCA) for point of care computing, developed the MCWs based on a unique perspective garnered from working closely with healthcare organizations over eight years. Completely integrated, the MCWs are supported by Motion, easing the burden on internal IT staff that often must contact multiple vendors to support or upgrade existing computer carts.

"With the introduction of the C5, Motion established itself as a leader in the rapidly evolving market for mobile point of care computing devices", said Marc Holland, managing director of System Research Services. "While the C5 is well-suited to many point-of-care workflows, no single form factor is suited to all. With its latest point of care solutions Motion again sets itself apart with a comprehensive and flexible set of offerings that allow hospitals to obtain a family of solutions from a single source that they can optimally match to each unique workflow to help improve the delivery of patient care."

MicoPhage launches trial for MRSA platform

MicroPhage (Longmont, Colorado) reported the launch of its multi-site clinical trial to support a FDA premarket notification. The platform has been developed to rapidly identify bacterial infections and determine antibiotic susceptibility or resistance to aid physicians in antibiotic management. The company's first product is designed to rapidly identify Staphylococcus aureus (staph) bacteria and determine methicillin resistance (MRSA) or susceptibility (MSSA) in suspected cases of bacteremia bacteria in the blood, in as little as 5 hours.

The MicroPhage test platform requires no instrumentation and is composed of two small reaction tubes for incubating blood culture specimens. After five hours, the incubated samples are added to a dual dipstick-like detector, which looks much like a pair of home pregnancy tests. One part of the detector shows if the sample is infected with S. aureus bacteria and the other shows if it is susceptible or resistant to the antibiotic. Results allow for more precise antibiotic therapy for a condition that has a mortality rate of 20% or more. Delivering this diagnostic information quickly will enable physicians to prescribe more effective and precise antibiotics that could shorten hospital stays, lower rising health care costs, and ultimately save lives.